WLWilliam Raymond Lumry

William Raymond Lumry

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


William Raymond Lumry has a total of 161 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Garadacimab in Hereditary Angioedema: Modeling Suggests Sustained Improvements in Attack‐Free Probability and Quality of Life Over 5 Years

    by Philip H. Li, F. Ida Hsu, Emel Aygören‐Pürsün, William R. Lumry, Jason Raasch, Ingo Pragst, Yinglei Li, Chiara Nenci, Marco Campioni, Markus Magerl

    Hereditary angioedema (HAE) attacks are recurrent, debilitating, and potentially life‐threatening. Across the clinical program, garadacimab long‐term prophylaxis demonstrated early onset and durable, sustained protection against HAE attacks and clinically meaningful improvements in health‐related quality of life (HRQoL). HAE treatment goals include total disease control (attack‐free) and normalization of life. Predicting treatment effect may aid shared decision‐making and choice of long‐term prophylaxis. Here, we report an attack‐free probability model predicting garadacimab treatment effect beyond available Phase 3 clinical data and explore the relationship between HRQoL and attack‐free duration. A generalized mixed‐effect Poisson model was developed and validated with data from the garadacimab pivotal Phase 3 (VANGUARD) and Phase 3 open‐label extension studies. Efficacy variables, including attack‐free probabilities, were predicted for simulated populations of garadacimab‐treated patients and assessed for goodness of fit. Analysis of covariance was used to assess the relationship between Angioedema Quality of Life questionnaire scores and attack‐free duration. Model‐predicted efficacy variables adequately reflected observed clinical data with high goodness of fit (Nakagawa–Schielzeth conditional R 2 : 74.3%). Following a 1‐month attack‐free period after garadacimab initiation, patients had a 60% cumulative probability of remaining attack‐free up to Month 25 and 49% up to 5 years. HRQoL improved with increasing duration of attack‐free periods, reaching minimal to no impairment after 6 months. This attack‐free probability model suggests long‐term effects of garadacimab over a 5‐year treatment period. Patients treated with garadacimab have the potential to live attack‐free for long periods of time, with substantial HRQoL improvements.

  • Open Access

    Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World Study

    by Jonathan A. Bernstein, Stephen D. Betschel, Paula J. Busse, Aleena Banerji, H. James Wedner, Michael Manning, Rafael H. Zaragoza-Urdaz, John Anderson, Remi Gagnon, Alan P. Baptist, et al.

    Introduction Lanadelumab is approved for long-term prophylaxis of hereditary angioedema (HAE) attacks in patients aged ≥ 2 years in the USA and aged ≥ 12 years in Canada. The EMPOWER Study (NCT03845400) evaluated the real-world effectiveness and safety of lanadelumab in male and female patients with HAE due to C1 inhibitor deficiency type 1 or 2 from the USA and Canada. Here, we report final, up to 36-month, data. Methods Patients aged ≥ 12 years were classified as newly treated with lanadelumab or established on lanadelumab (receiving < 4 and ≥ 4 lanadelumab doses at enrollment, respectively). The primary objective was effectiveness of lanadelumab as measured by HAE attack rate before and after lanadelumab initiation. Safety data were collected. Results A total of 109 patients received ≥ 1 lanadelumab dose and had ≥ 1 post-baseline safety assessment. Patients were 40.9 (17.4) years of age (mean [standard deviation (SD)]), majority (72/109; 66.1%) female, 37/109 (33.9%) male, and over 90% white. Patients newly treated with and established on lanadelumab received lanadelumab for 737.7 (374.5) (mean [SD]) and 907.1 (469.3) days, respectively, during the study. In patients newly treated with lanadelumab, the mean (95% confidence interval) observed attack rate (attacks/month) decreased by 85% after lanadelumab initiation, from 1.42 (0.34–2.50) pre-lanadelumab to 0.20 (0.02–0.38) post-lanadelumab initiation (cumulative period). Patients established on lanadelumab had an observed attack rate of 0.20 (0.10–0.30) during 36 months’ follow-up. Of 154 treatment-emergent adverse events (TEAEs), no injection site reactions were reported and 6 (in 2 patients) were considered related to lanadelumab; no lanadelumab-related TEAEs were serious. Conclusion Real-world data from EMPOWER showed marked HAE attack rate reduction up to 36 months after initiating lanadelumab in patients newly treated with lanadelumab and maintenance of low attack rates in patients established on lanadelumab. No new safety signals were identified. Trial Registration ClinicalTrials.gov, identifier NCT03845400. Graphical abstract available for this article. Graphical Abstract


  • Open Access

    An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema

    by Robbin Itzler, William R. Lumry, John Sears, Julia Braverman, Yinglei Li, Caroline J. Brennan, Gary G. Koch

    Background: Hereditary angioedema (HAE) is characterized by unpredictable and often severe cutaneous and mucosal swelling that affects the extremities, face, larynx, gastrointestinal tract, or genitourinary area. Introduction of novel long-term prophylactic treatment options (lanadelumab, berotralstat, and C1-esterase inhibitor SC [human]) into the treatment armamentarium has substantially reduced HAE attacks, allowing patients to be attack free for longer with improvements to their quality of life. Using data drawn from a wide-ranging survey of patients with HAE, we examined the relationship between duration of time attack free and health-related quality of life (HRQoL), exploring the possibility that there is an association between observed improvement in HRQoL and attack-free duration. Methods: A survey among patients with HAE on long-term prophylaxis (LTP) in six countries (the US, Australia, Canada, UK, Germany, and Japan) assessed the relationship between attack-free duration and mean Angioedema Quality of Life (AE-QoL) scores, quality of life benefits, and rescue medication used. Analysis of covariance (ANCOVA) was used to assess the roles of LTP and attack-free period (< 1 month, 1– < 6 months, ≥ 6 months) on total AE-QoL scores. Results include descriptive p-values for strength of association, without control for multiplicity. Descriptive statistics were used to show the relationship between time attack free and quality of life benefits. Results: Longer durations of time for which participants reported being attack free at the time of the survey correlated with better AE-QoL scores and less use of rescue medication. The mean total AE-QoL scores were 51.8, 33.2, and 19.9 for those who reported having been attack free for < 1 month, 1– < 6 months, and ≥ 6 months, respectively, with higher scores reflecting more impairment. The ANCOVA results showed a strong association between attack-free duration and AE-QoL total score. Conclusion: This study shows that longer attack-free duration has an influential role for better HRQoL in patients receiving LTP. Prolonging the attack-free period is an important goal of therapy and recent advances in LTP have increased attack-free duration. However, opportunities exist for new treatments to further increase attack-free duration and improve HRQoL for all patients with HAE.


  • Open Access

    Long-term lanadelumab treatment improves health-related quality of life in patients with hereditary angioedema

    by William R. Lumry, Marcus Maurer, Karsten Weller, Marc A. Riedl, Maureen Watt, Ming Yu, Giovanna Devercelli, Juliette Meunier, Aleena Banerji


  • Triggers of Exacerbation in Chronic Urticaria and Recurrent Angioedema—Prevalence and Relevance

    by Anete Sevciovic Grumach, Petra Staubach-Renz, Ricardo Cardona Villa, Susana Diez-Zuluaga, Imke Reese, William R. Lumry


  • Open Access

    Impact of lanadelumab on health‐related quality of life in patients with hereditary angioedema in the HELP study

    by William R. Lumry, Karsten Weller, Markus Magerl, Aleena Banerji, Hilary J. Longhurst, Marc A. Riedl, Hannah B. Lewis, Peng Lu, Giovanna Devercelli, Gagan Jain, et al.

    Background: An objective of the phase 3 HELP Study was to investigate the effect of lanadelumab on health‐related quality of life (HRQoL) in patients with hereditary angioedema (HAE).Methods: Patients with HAE‐1/2 received either lanadelumab 150 mg every 4 weeks (q4wks; n = 28), 300 mg q4wks (n = 29), 300 mg every 2 weeks (q2wks; n = 27), or placebo (n = 41) for 26 weeks (days 0–182). The Angioedema Quality of Life Questionnaire (AE‐QoL) was administered monthly, consisting of four domain (functioning, fatigue/mood, fears/shame, nutrition) and total scores. The generic EQ‐5D‐5L questionnaire was administered on days 0, 98, and 182. Comparisons were made between placebo and (a) all lanadelumab‐treated patients and (b) individual lanadelumab groups for changes in scores (day 0–182) and proportions achieving the minimal clinically important difference (MCID, −6) in AE‐QoL total score.Results: Compared with the placebo group, the lanadelumab total group demonstrated significantly greater improvements in AE‐QoL total and domain scores (mean change, −13.0 to −29.3; p < 0.05 for all); the largest improvement was in functioning. A significantly greater proportion of the lanadelumab total group achieved the MCID (70% vs 37%; p = 0.001). The lanadelumab 300 mg q2wks group had the highest proportion (81%; p = 0.001) and was 7.2 times more likely to achieve the MCID than the placebo group. Mean EQ‐5D‐5L scores at day 0 were high in all groups, indicating low impairment, with no significant changes at day 182.Conclusion: Patients with HAE‐1/2 experienced significant and clinically meaningful improvements in HRQoL measured by AE‐QoL following lanadelumab treatment in the HELP Study.


  • Open Access

    Advances in Hereditary Angioedema: The Prevention of Angioedema Attacks With Subcutaneous C1-Inhibitor Replacement Therapy

    by William Lumry, Teri Lvn Templeton, Laurel Omert, Donald Levy

    Hereditary angioedema (HAE) is a debilitating condition caused by a functional C1-inhibitor (C1-INH) deficiency and characterized clinically by episodes of subcutaneous or submucosal swelling. C1-INH replacement is highly effective for preventing HAE attacks and can improve health-related quality of life. Once available only for intravenous use, C1-INH is now available as a subcutaneous formulation for self-administration, shown to provide sustained plasma levels of C1-INH and reducing the monthly median HAE attack rate by 95% versus placebo in the phase 3 COMPACT study. Subcutaneously administered C1-INH satisfies multiple unmet needs in the management of patients with HAE.


  • Open Access

    Immune Globulin Subcutaneous, Human – Klhw 20% for Primary Humoral Immunodeficiency: An Open-Label, Phase III Study

    by John W Sleasman, William R Lumry, Iftikhar Hussain, H James Wedner, James B Harris, Kecia L Courtney, Elsa Mondou, Jiang Lin, Mark R Stein

    Aim: This prospective, Phase III study assessed the pharmacokinetics (PK), safety and tolerability of immune globulin subcutaneous, human – klhw 20% solution (IGSC-C 20%) in participants with prima... Lay abstract This clinical trial studied a new US FDA-approved product, immune globulin subcutaneous, human – klhw 20% solution (IGSC-C 20%), to treat primary humoral immunodeficiency (PI), a group...


  • Open Access

    Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH-HAE: SAHARA Randomized Study

    by William R. Lumry, Inmaculada Martinez-Saguer, William H. Yang, Jonathan A. Bernstein, Joshua Jacobs, Dumitru Moldovan, Marc A. Riedl, Douglas T. Johnston, H. Henry Li, Yongqiang Tang, et al.